Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus BRIMONIDINE TARTRATE AND TIMOLOL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus BRIMONIDINE TARTRATE AND TIMOLOL MALEATE.
BETAPACE vs BRIMONIDINE TARTRATE AND TIMOLOL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Brimonidine tartrate is a selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol maleate is a non-selective beta-adrenergic receptor antagonist that decreases aqueous humor production by blocking beta-2 receptors in the ciliary epithelium.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
One drop in the affected eye(s) twice daily (approximately 12 hours apart).
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Brimonidine: ~2.9 hours (terminal) after ophthalmic administration. Timolol: ~4 hours (terminal); clinically, systemic exposure is low due to topical route.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Brimonidine: ~74% renal (unchanged and metabolites), ~22% fecal. Timolol: ~20% renal (unchanged), ~80% hepatic metabolism with biliary and fecal elimination.
Category C
Category A/B
Beta-Blocker
Beta-Blocker